Intra-individual, randomized multicentric comparison of the MRI contra
Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Gadobutrol
Diagnostic agent
Compared with
- Gadoteric acid
What it measured
Main measures
Overall assessment of contrast enhancement on a 3-point scale (equal – better – worse) in a matched pair assessment of both contrast agents.
Who could take part
Early (CIS/RIS)
Show the full criteria
Inclusion criteria
Inclusion: 1. adult patients, age 18-85 years Exclusion: Patients …
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of the study is to prove, that Gadovist® 1.0 provides superior contrast enhancement characteristics of MS lesions as compared to Dotarem®, thereby providing superior information for further diagnostic and / or therapeutic decisions.
Loading reviews and guidelines…
Related trials
- The Inflammatory Process and the Medical Imaging in Patients With an I
Phase 2 · Stopped early
Stopped
History
Started
Dec 2009